CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma.

9506Background: In the phase 3 CheckMate 067 trial, a durable and sustained clinical benefit was achieved with nivolumab (NIVO) + ipilimumab (IPI) and NIVO alone vs IPI at 5-y of follow-up (overall...